Eleven Biotherapeutics presents data on protein therapeutics for anterior, posterior eye diseases

Article

During the Association for Research in Vision and Ophthalmology meeting last week, Eleven Biotherapeutics presented data for 2 of its protein therapeutics, which demonstrate the role of cytokine biology to target both anterior and posterior eye diseases.

Orlando, FL-During the Association for Research in Vision and Ophthalmology meeting last week, Eleven Biotherapeutics presented data for 2 of its protein therapeutics, which demonstrate the role of cytokine biology to target both anterior and posterior eye diseases. 

According to the company, clinical data on it’s lead drug candidate, EBI-005, “EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, demonstrated improvements in signs and symptoms of dry eye disease (DED), including reduction in ocular pain and artificial tear use. In addition, preclinical data on EBI-029, an IL-6 (Interleukin-6) inhibitor optimized for localized ocular administration in diabetic macular edema (DME), has demonstrated that EBI-029 potently inhibits IL-6 signaling in vitro. IL-6 is a cytokine that has previously been shown to be upregulated in DME, contributing to the angiogenic and inflammatory components of the disease and correlating with disease severity. By inhibiting IL-6, EBI-029 could offer an alternative to current standard of care, including anti-VEGF therapies.”

EBI-005 is being evaluated in a Phase 3 clinical study in patients with DED and a Phase 2 clinical study in patients with allergic conjunctivitis. And EBI-029 is in preclinical development for the treatment of DME. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, expresses excitement for emerging retinal therapies
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Dr Steven Ferrucci at Controversies in Modern Eyecare 2025
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
Patricia Buehler, MD, MPH, at ASCRS 2025
Brett Bielory, MD, at ASCRS 2025
© 2025 MJH Life Sciences

All rights reserved.